Tocilizumab

Interleukin-6 Receptor Antagonist — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Tocilizumab is a drug in the Interleukin-6 Receptor Antagonist class catalogued in DrugCentral. It was first approved by the PMDA in 2008. Its mechanism of action is classified as Interleukin 6 Receptor Antagonists. DrugCentral lists 1 molecular target, including IL6R. Recorded indications include Castleman's disease, Cytokine release syndrome induced by tumor-specific T-cell infusion therapy, Giant cell arteritis and Juvenile idiopathic arthritis.

• Drug class: Interleukin-6 Receptor Antagonist.
• Mechanism of action: Interleukin 6 Receptor Antagonists.
• Molecular targets: IL6R (1 listed in DrugCentral).
• Indications: Castleman's disease, Cytokine release syndrome induced by tumor-specific T-cell infusion therapy, Giant cell arteritis, Juvenile idiopathic arthritis and Juvenile idiopathic arthritis, extended oligoarthritis and others.
• ATC code: L04AC07 (Interleukin inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (11)

• Castleman's disease
• Cytokine release syndrome induced by tumor-specific T-cell infusion therapy
• Giant cell arteritis
• Juvenile idiopathic arthritis
• Juvenile idiopathic arthritis, extended oligoarthritis
• Juvenile rheumatoid arthritis
• Juvenile seronegative polyarthritis
• Juvenile seropositive polyarthritis
• Pneumonia caused by Severe acute respiratory syndrome coronavirus 2
• Rheumatoid arthritis
• Still's disease

Mechanism & targets

• Mechanism of action (MoA): Interleukin 6 Receptor Antagonists
• Established pharmacologic class: Interleukin-6 Receptor Antagonist

Molecular targets (1)

Target	Gene	Action	Activity
Interleukin-6 receptor subunit alpha	IL6R	other	—

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2010-01-08	FDA	—	GENENTECH
2009-01-16	EMA	—	Chugai Pharmaceutical Co., Ltd
2008-03-06	PMDA	—	Chugai Pharmaceutical Co., Ltd

ATC classification

ATC code	Therapeutic hierarchy
L04AC07	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Contraindicated product administered	6885.5
Joint swelling	5742.8
Synovitis	5298.2
Drug ineffective	4775.9
Arthropathy	4698.0
Drug intolerance	4540.3
Treatment failure	4139.3
Pemphigus	4115.3
Systemic lupus erythematosus	3906.9
Therapeutic product effect decreased	3670.7
Glossodynia	3603.7
Hand deformity	3419.5

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 375823-41-9
• InChIKey: —
• PubChem CID: 10150081

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tocilizumab used for?

DrugCentral lists the following indications for Tocilizumab: Castleman's disease, Cytokine release syndrome induced by tumor-specific T-cell infusion therapy, Giant cell arteritis, Juvenile idiopathic arthritis, Juvenile idiopathic arthritis, extended oligoarthritis, Juvenile rheumatoid arthritis, Juvenile seronegative polyarthritis and Juvenile seropositive polyarthritis and others.

How does Tocilizumab work?

Tocilizumab is classified as Interleukin 6 Receptor Antagonists; its molecular targets in DrugCentral include IL6R.

When was Tocilizumab first approved?

Tocilizumab was first approved by the PMDA in 2008.

What drug class does Tocilizumab belong to?

Tocilizumab is in the Interleukin-6 Receptor Antagonist class.

Sources

• DrugCentral drug card 4933 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1237022 — compound record and bioactivity
• PubChem CID 10150081 — chemical identifiers
• DrugBank DB06273 — drug record
• FDA UNII I031V2H011 — substance identity
• DailyMed: FDA labels for Tocilizumab — current prescribing information (label search)
• UniProt P08887 (IL6R) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.